Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kitasato Institute, Sumitomo Dainippon’s KSP-1007 Enters US PI Study for Carbapenem-Resistant Bacterial Infections
January 14, 2022
- Keytruda, Opdivo Neck and Neck in 2021; 6 Drugs Cross 100 Billion Yen Mark: Encise
January 13, 2022
- Sawai to Launch E Keppra Granule Tablets on Feb. 1
January 13, 2022
- Daiichi Sankyo to Shutter Plexxikon to Maximize Investment in ADCs
January 13, 2022
- Ex-CMIC Exec Philippe Auvaro Joins Medical Data Vision
January 12, 2022
- Takeda Pushes Back Assumed Biosimilar Entry in US by 3-5 Years
January 12, 2022
- Takeda to Buy Adaptate to Bolster I/O Pipeline
January 12, 2022
- Japan Ethical Drug Sales Zoom 8.9% in November: Crecon
January 12, 2022
- Gilead Names US VP Kennet Brysting as New Japan Chief
January 12, 2022
- Mitsubishi Chemical Holdings Plans Organizational Rejig in April, Ueno to Helm Pharma Unit
January 11, 2022
- Kissei/Maruishi’s Pruritus Drug Hits Mark in Japan PIII Study
January 11, 2022
- Rexulti Expands Label into Pediatric Schizophrenia in US
January 11, 2022
- Sosei Inks GPCR Strategic Collaboration with Google’s Verily
January 11, 2022
- Takecab Tops Japan Sales Ranking in December: Encise
January 11, 2022
- Riken Genesis’s AmoyDx Now Available as CDx for Takeda’s ALK Inhibitor Alunbrig
January 7, 2022
- Eisai Awards Exclusive Rights for Splicing Modulator H3B-8800 to Roivant
January 7, 2022
- Opdivo Gets Adjuvant Nod for Esophageal Cancer in Taiwan: Ono
January 6, 2022
- Shionogi’s COVID-19 Pill Submission Delaying into 2022 as Recruitment Hits Snag
January 6, 2022
- Detailing Activities Rise in All Promotion Channels MOM, YOY in November: Intage
January 6, 2022
- Nexium and Feburic Generic Debuts Eyed in 2022, but with Caution to Avoid Shortages
January 5, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…